Special Issue

Resistance and Evolving Biology in Mycobacteria: Multidisciplinarity as a Contemporary Approach

Message from the Guest Editors

Drug resistance stands recognized as one of the major challenges to effective tuberculosis (TB) control worldwide. Mycobacterium tuberculosis is considered the leading cause of drug-resistant airborne epidemics globally. M. tuberculosis strains are classified into seven primary phylogenetic lineages and multiple sublineages, each of which has co-evolved with its host population, resulting in differing propensities for resistance development and, consequently, varied therapeutic outcomes. Despite this, many mutations observed in resistant strains have not yet been conclusively linked to resistance, and numerous resistant strains remain uncharacterized at the molecular genetic level. Even with the availability of potent last-line anti-TB drugs, around half of those infected still succumb to the disease. In this Special Issue, we will highlight original and review articles that explore the diverse aspects of M. tuberculosis evolutionary biology in the context of resistance, emphasizing a multidisciplinary research approach. We look forward to receiving your papers and are very grateful to have the opportunity to collaborate with you.

Guest Editors

Dr. Irena Arandjelovic

Institute of Microbiology and Immunology, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia

Prof. Dr. Dragana Vukovic

Institute of Microbiology and Immunology, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia

Deadline for manuscript submissions

30 November 2025

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/si/219238

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI